RCT: Axicabtagene Ciloleucel as second-line therapy for Large B-Cell Lymphoma.

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma – New England Journal of Medicine

Commentary: ZUMA-7 Primary Analysis: Second-Line Axicabtagene Ciloleucel Quadruples Event-Free Survival in Large B-Cell Lymphoma – The ASCO POST

Commentary on Twitter

In a trial involving patients with relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to significantly longer event-free survival than standard salvage chemotherapy. #ASH21 https://t.co/V1WfVJ2k9V pic.twitter.com/ZHUhx8es27

— NEJM (@NEJM) December 11, 2021